Effects of 3-month nifedipine treatment on endocrine-metabolic parameters in patients with abdominal obesity and mild hypertension

Journal of Endocrinological Investigation

Volumn 21, Issue 1, 1998, Pages 56-63

  Maccario, M ^a   Oleandri, S E ^a   Avogadri, E ^a   Rossetto, R ^a   Grottoli, S ^a   Procopio, M ^a   Camanni, F ^a   Ghigo, E ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

Blood pressure; DHEA S; Glucose; IGF I; Insulin; Nifedipine; Obesity

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; GLUCOSE; INSULIN; NIFEDIPINE; PRASTERONE SULFATE;

ADULT; ARTICLE; BODY MASS; BORDERLINE HYPERTENSION; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; INSULIN RESISTANCE; LOW CALORY DIET; MALE; OBESITY; ORAL GLUCOSE TOLERANCE TEST; SYSTOLIC BLOOD PRESSURE;

EID: 0031934605     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03347287     Document Type: Article

References (45)

1. Karam J.H., Grodsky G.M., Forsham P.H. Excessive insulin response to glucose in obese subjects measured by immunochemical assay. Diabetes 12: 197, 1963.
2. Polosky K.S., Given B.D., Van Cauter E. 24-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J. Clin. Invest. 82: 442, 1988.
3. Koman O.G., Insel J., Saekow M., Olefky J.M. Mechanism of insulin resistance in human obesity. Evidence for receptor and post-receptor defects. J. Clin. Invest. 65: 1273, 1980.
4. Reaven G.M. Role of insulin resistance in human disease. Diabetes 37: 1595, 1988.
5. Stamler R., Stamler J., Riedlinger W.F., Algera G., Roberts R.H. Findings in hypertension screening of 1 million Americans. JAMA 240: 1607, 1978.
6. Landsberg L. Hyperinsulinemia: possible role in obesity-induced hypertension. Hypertension 19 (suppl I): 1-61, 1992.
7. DeFronzo R.A., Ferranini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14: 3, 1991.
8. Landsberg L., Krieger D.L. Obesity, metabolism and the sympathetic nervous system. Am. J. Hypertens. 2: 1255, 1989.
9. Ferranini E. Insulin and blood pressure: possible role of haemodynamics. Clin. Exp. Hypertens. A14: 271, 1992.
10. Ganrot P.O. Insulin resistance syndrome: possible key role of blood flow in resting muscle. Diabetologia 36: 876, 1993.
11. Beer N.A., Jakubowicz D.J., Beer R.M., Arocha I.R., Nestler J.E. Effects of nitrendipine on glucose tolerance and serum insulin and dehydroepiandrosterone sulfate levels in insulin resistant obese and hypertensive men. J. Clin. Endocrinol. Metab. 76: 178, 1993.
12. Tuck M.L., Bravo E.L., Krakof L.R., Friedman C.P., and the Modern Approach to the Treatment of Hypertension Study Group. Endocrine and renal effects of nifedipine gastrointestinal therapeutic system in patients with essential hypertension. Results of a multicentre trial. Am. J. Hypertens. 3: 333s, 1990.
13. Valensi P., Uzzan B., Attali J.R., Perret G. Effects of nifedipine and nitrendipine in insulin secretion in obese patients. J. Cardiovasc. Pharmacol. 78 (suppl 1): s91, 1991.
14. Charles S., Ketekslegers J., Lambert A. Hyperglycemic effect of nifedipine. Br. Med. J. 283: 19, 1981.
15. Giuliano D., Torella R., Cacciapuoti F., Gentile S., Verza M., Varricchio M. Impairment of insulin secretion by nifedipine. Eur. J. Clin. Pharmacol. 18: 395, 1980.
16. Stein P.P., Black H.R. Drug treatment of hypertension in patient with diabetes mellitus. Diabetes Care 14: 425, 1991.
17. Marin P., Kvist H., Lindstedt G., Sjostrom L., Biontorp P. Low concentration of insulin-like growth factor-I in abdominal obesity. Int. J. Obes. 17: 83, 1993.
18. Jakubowicz D.J., Beer N.A., Beer R.M., Nestler J.E. Disparate effects of weight reduction by diet on serum dehydroepiandrosterone-sulfate levels in obese men and women. J. Clin. Endocrinol. Metab. 80: 3373, 1995.
19. Rasmussen M.H., Hvidberg A., Juul A., Main K.M., Gotfredsen A., Shakkebae N.E., Hilsted J. Massive weight loss restores 24-hour growth hormone release profiles and serum insulin-like growth factor-I levels in obese subjects. J. Clin. Endocrinol. Metab. 80: 1407, 1995.
20. Thissen J.P., Ketelslegers J.M., Underwood L.E. Nutritional regulation of the insulin-like growth factors. Endocr. Rev. 15: 80, 1994.
21. Nestler J.E., Clore J.N., Strauss J.F., Blackard W.G. The effect of hyperinsulinemia on serum testosterone, progesterone, dehydroepiandrosterone sulfate, and cortisol levels in normal women and in a woman with hyperandrogenism, insulin resistance, and acanthosis nigricans. J. Clin. Endocrinol. Metab. 64: 180, 1987.
22. Houston B., O'Neil I.E. Insulin and growth hormone act synergistically to stimulate insulin-like growth factor-I production by cultured chicken hepatocytes. J. Endocrinol. 128: 389, 1991.
23. Jones J.I., Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 16: 1, 1995.
24. Fifth Report on the Joint National Committee on Detection, evaluation, and treatment of high blood pressure (JNC V). Arch. Intern. Med. 153: 154, 1993.
25. Caro J.F. Insulin resistance in obese and nonobese man. J. Clin. Endocrinol. Metab. 73: 691, 1991.
26. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28: 1039, 1979.
27. Devis G., Somers, Van Obberghen E., Malaisse W.J. Calcium antagonists and islet function. Inhibition by verapamil. Diabetes 24: 547, 1975.
28. Dominic J., Miller R.E., Anderson J., McAllister R. Pharmacology of verapamil. Impairment of glucose tolerance by verapamil in the conscious dog. Pharmacology 20: 196, 1980.
29. Westfall M.V., Sayeed M.M. Effect of diltiazem on skeletal muscle 3-O-methyl-glucose transport in bacteriemic rats. Am. J. Physiol. 256: R716, 1989.
30. Bursztyn M., Raz I. Mekler J., Ben-Ishay D. Nitrendipine improves glucose tolerance and deoxyglucose uptake in hypertensive rats. Hypertension 23: 1051, 1994.
31. Andronico G., Piazza G., Mangano M.T., Mula G., Cerasola G. Nifedipine vs enalapril in treatment of hypertensive patients with glucose intolerance. J. Cardiovasc. Pharmacol. 18(Suppl. 1): 552, 1991.
32. Giugliano D., Saccomanno F., Paolisso G., et al. Nicardipine does not cause deterioration of glucose homeostasis in man: a placebo controlled study in elderly hypertensive with and without diabetes mellitus. Eur. J. Clin. Pharmacol. 43: 39, 1992.
33. Morris A.D., Donnelly R., Connel J.M.C., Reid J.L. Metabolic effects of lacidipine: a placebo-controlled study using the euglycemic hyperinsulinemic clamp. Br. J. Clin. Pharmacol. 35: 40, 1993.
34. Shen W.H.H., Swislockii A.L.M., Hoffman B., Chen Y.-D.Z., Reaven G.M. Comparison of the effects of atenolol and nitrendipine on glucose, insulin and lipid metabolism in patients with hypertension. Am. J. Hypertens. 4: 199, 1991.
35. Byyny R.L., Lo Verde M., Lloyd S., et al. Cytosolic calcium and insulin resistance in elderly patients with essential hypertension. Am. J. Hypertens. 5: 459, 1992.
36. Draznin B., Susman K.E., Echel R.H., Kao M., Yost T., Sherman N.A. Possible role of cytosolic free calcium concentrations in mediating insulin resistance of obesity and hyperinsulinemia. J. Clin. Invest. 82: 1848, 1988.
37. Fagerberg B., Andersson O.K., Isaksson B., Biontorp P. Blood pressure control during weight reduction in obese hypertensive men: separate effects of sodium and energy restriction. Br. Med. J. 288: 7, 11, 1984.
38. Schnock E.D., Buffington C.K., Hubert G.D., et al Divergent correlation of circulatory dehydroepiandrosterone sulfate and testosterone with insulin levels and insulin receptors binding. J. Clin. Endocrinol. Metab. 66: 1329, 1988.
39. Hafner S.M., Valdez R.A., Mykkanen L., Stern M.P., Kats M.S. Decreased testosterone and dehydroepiandrosterone sulfate concentrations are associated with increased insulin and glucose concentration in non diabetic men. Metabolism 43: 599, 1994.
40. Pasquali R., Cantobelli S., Vicennati V., Casimirri F., Spinucci G., De Iasio R., Mesini P., Boschi S., Nestler J.E. Nitrendipine treatment in women with polycystic ovarian syndrome : evidence for a lack of effects of calcium channel blockers on insulin, androgens and sex hormone-binding globulin. J. Clin. Endocrinol. Metab. 80: 3346, 1995.
41. Clemmons D.R., Van Wyk J.J. Factors controlling blood concentrations of somatomedin C. J. Clin. Endocr. Metab. 13: 113, 1984.
42. Villafuerte B.C., Koop B.L., Pao C.I., Phillips L.S. Glucocorticoid regulation of insulin-like growth factor-binding protein-3. Endocrinology 136: 1928, 1995.
43. Veldhuis J.D., Iranmanesh A., Ho K.K.Y., et al. Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man. J. Clin. Endocrinol. Metab. 72: 51, 1991.
44. Williams T., Berelowitz M., Joffe S.N., et al. Impaired growth hormone responses to growth hormone-releasing factor in obesity. N. Engl. J. Med. 311: 1403, 1984.
45. Poulos J.E., Legget-Frazier N., Khazanie P., Long S., Sportsman R., MacDonald K., Caro J.F. Circulating insulin-like growth factor I concentrations in clinically severe obese patients with and without NIDDM in response to weight loss. Horm. Metab. Res. 26: 478, 1994.